Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension
J. Clin. Invest. 111:9 doi:10.1172/JCI17500 [Go to this article.]
Options: View larger image (or click on image)
Medium
Table 2

Hemodynamic variables and exercise capacity in eight patients with PPH treated with inhaled VIPA

Copyright © 2009, The American Society for Clinical Investigation.
Copying, redistribution, and other usage policies